Bionomics
phase prevail social anxiety disorder trial cost effective trial with an efficacy conducive to rapid data generation ability to leverage development plan and trial design for social anxiety disorder received clearance for filing and fast track designation phase trial underway and will read out topline data by end of fast track designation topline data fees | Bionomics
Company
Deck Type
Sector
Industry
Deck date
April 2022
Slide
13 of 38
Similar slides by Bionomics
See diffirences between slides (animation)
Investor Presentation
October 2022
phase social anxiety disorder trial prevail | Bionomics
IPO
December 2021
lin | Bionomics
Related slides by other companies
MindMed
Investor Presentation
September 2023
phase generalized anxiety disorder gad | MindMed
MindMed
Investor Presentation
June 2023
phase generalized anxiety disorder gad | MindMed
MindMed
Investor Day
June 2023
phase generalized anxiety disorder gad | MindMed
MindMed
Investor Presentation
August 2023
phase generalized anxiety disorder gad | MindMed
Other recent decks by Bionomics
See all presentations (5 decks)
Results
March 2023
Investor Presentation
October 2022
Investor Presentation
June 2022
IPO
December 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io